Molecular Mechanisms of VWF Alteration in Vitro/Vivo

VWF 体外/体内改变的分子机制

• 批准号: 8999000
• 负责人: ROBERT R MONTGOMERY
• 金额: $ 31.64万
• 依托单位: VERSITI WISCONSIN, INC.
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至 2018-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8999000
• 关键词: ADAMTS; Address; Amino Acid Sequence; Binding; Biology; Blood Circulation; Blood Coagulation Disorders; Blood Platelets; Blood Vessels; Blood typing procedure; Carbohydrates; Carrier Proteins; Cells; Characteristics; Clinical; Code; Complex; DDAVP; Data Analyses; Defect; Development; Disease; Elements; Factor VIII; Genotype; Goals; Grant; Half-Life; Hemostatic function; Human; In Vitro; Individual; Inherited; Injury; Instruction; Knowledge; Lead; Mediating; Modeling; Modification; Molecular; Mus; Mutation; Organ; Pathogenesis; Patients; Phenotype; Plasma; Play; Predisposition; Process; Production; Proteins; Proteolysis; Recombinants; Reporting; Role; Site; System; Testing; Time Factors; Tissues; Variant; base; blood group; disease phenotype; effective therapy; extracellular; in vivo; mouse model; mutant; novel; programs; residence; treatment choice; treatment strategy; von Willebrand Disease; von Willebrand Factor

PROJECT SUMMARY (See instructions); Decreased VWF levels or defects in VWF function cause von Willebrand disease (VWD) the most common inherited bleeding disorder. The reduced plasma survival of VWF is a novel mechanism causing type 1 VWD (type IC) and may represent 10-15% of type 1 VWD cases. While our studies have defined the characteristic elements of the type IC phenotype, very little is known about the mechanisms governing VWF clearance under normal or pathological conditions. Our goal is to define VWF clearance mechanisms. We have identified many novel mutations in the VWF coding region for VWD patients. These novel sequence variations are distributed throughout all domains within the VWF protein. Our previous expression studies revealed that type 2A VWD results from a complex intersection of mechanisms: defective secretion, multimerization, regulated storage, or ADAMTSI 3 susceptibility. The 2A mutations, when co-expressed with wild-type VWF, appeared to negatively impact at least one mechanism important for normal VWF processing. While decreased secretion and reduced plasma survival have been implicated as mechanisms causing type 1 VWD, the impact of type 1 mutations on multimerization, regulated storage/secretion, and ADAMTSI 3-mediated degradation is not well-defined. We will define the mechanisms causing type 1 VWD and develop a model that would allow one to predict the impact of mutations on VWD phenotype. ADAMTSI 3-mediated proteolysis of VWF clearly plays a crucial role in type 2A VWD. Some studies have suggested that ADAMTSI 3 may also contribute to the type 1 VWD phenotype. A percentage of ADAMTSI 3 is reported to bind to circulating VWF and thus may be cleared quickly in type IC VWD patients. We will determine if type 1 VWF variants have increased susceptibility to ADAMTS-13 proteolysis and examine if ADAMTSI3 levels are reduced in type IC VWD. The knowledge gained from these studies will increase our understanding of mechanisms causing VWD, leading to the development of more effective treatment strategies

项目总结（见说明）; VWF水平降低或VWF功能缺陷导致血管性血友病（VWD）是最常见的遗传性出血性疾病。VWF的血浆存活率降低是导致1型VWD（IC型）的新机制，可能占1型VWD病例的10-15%。虽然我们的研究已经确定了IC型表型的特征元素，但对正常或病理条件下VWF清除的机制知之甚少。我们的目标是确定VWF清除机制。 我们已经确定了许多新的突变VWF编码区的VWD患者。这些新的序列变异分布在VWF蛋白的所有结构域中。我们以前的表达研究表明，2A型VWD的结果从一个复杂的交叉机制：分泌缺陷，多聚化，调节存储，或ADAMTSI 3的敏感性。当与野生型VWF共表达时，2A突变似乎对正常VWF加工的至少一种重要机制产生负面影响。虽然分泌减少和血浆存活减少被认为是导致1型VWD的机制，但1型突变对多聚化、调节储存/分泌和ADAMTSI 3介导的降解的影响尚未明确。我们将定义导致1型VWD的机制，并开发一个模型，使人们能够预测VWD表型突变的影响。 ADAMTS 13介导的VWF蛋白水解在2A型VWD中明显起关键作用。一些研究表明，ADAMTSI 3也可能有助于1型VWD表型。据报道，一定百分比的ADAMTSI 3与循环VWF结合，因此在IC型VWD患者中可快速清除。我们将确定1型VWF变体是否增加了对ADAMTS-13蛋白水解的敏感性，并检查IC型VWD中ADAMTSI 3水平是否降低。 从这些研究中获得的知识将增加我们对VWD机制的理解，从而开发更有效的治疗策略